Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY24 results · Oct–Dec 2023
Glenmark Pharmaceuticals reported revenue from operations of ₹2,506.70 crore (down 27.6% from Q3 FY23) and net loss of ₹330.82 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,506.70 | 3,463.86 | −27.6% | 3,207.38 | −21.8% |
| Other income | 45.41 | 76.42 | −40.6% | 1.70 | 27x |
| Total income | 2,552.11 | 3,540.27 | −27.9% | 3,209.07 | −20.5% |
| Profit before tax | (521.38) | 471.00 | Turned loss | (124.36) | Loss widened |
| Net profit for the period | (330.82) | 290.76 | Turned loss | (63.55) | Loss widened |
| Attributable to shareholders of the company | (351.38) | — | — | (81.95) | Loss widened |
| EPS, basic (₹) | (12.45) | 9.66 | Turned loss | (2.90) | Loss widened |
| Net margin (%) | -13.2 | 8.4 | -2.0 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,365.10 | 2,161.47 | −36.8% | 2,233.42 | −38.9% |
| Other income | 258.81 | 89.73 | +188.4% | 46.22 | +460.0% |
| Total income | 1,623.91 | 2,251.20 | −27.9% | 2,279.63 | −28.8% |
| Profit before tax | (75.50) | 589.13 | Turned loss | 389.37 | Turned loss |
| Net profit for the period | (20.41) | 430.50 | Turned loss | 302.35 | Turned loss |
| EPS, basic (₹) | (0.72) | 15.26 | Turned loss | 10.72 | Turned loss |
| Net margin (%) | -1.5 | 19.9 | 13.5 |
Consolidated
- Filed with BSE
- 15 Feb 2024, 11:03 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2024, 11:03 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE